Publications
Ultee ME. New Directions in Bioprocess Developement & Manufacturing, Bioprocess International 18(3):12-15, 2020.
Ultee ME. Top Trends in Bioprocessing for the Next Five Years, BioProcess Online, Oct 24, 2018.
Manzi AE & Ultee ME. Effective CMC Strategy for Biosimilar Development, Chapter in book “Biosimilars: Aspects of Regulatory, Clinical and Biopharmaceutical Development, H. Gutka (ed), Springer AG, 2018.
Ultee, ME & Easton, R. Implications of Cell Culture Conditions on Protein Glycosylation, Biopharm International, 28(11): 20-25, 2015.
Ultee, ME. The Road to the Biologic IND, American Pharmaceutical Review, (18):5 52-58, 2015.
Ultee, ME. Therapeutic Fc-Fusion Proteins, Book Review published in MAbs, 6:4: 810-811, July/August 2014.
Ultee, ME. CMO's Contribution to Bioprocessing, in 11th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production: 61-63, April 2014.
Ultee, ME. Flexibility in Bioprocessing, European Biopharmaceutical Review, Spring 2014, p44-47.
Ultee, ME. New HAE Drug Candidate from Dyax Produced by Laureate Biopharma, Aug 26, 2013, Press Release.
Ultee, ME. Single-Use Technologies Applied Throughout the Development and Manufacturing of Biopharmaceuticals. Bioresearch Online, Guest Column, June
20, 2013.
Ultee, ME. A 25-Year Retrospective on Bioprocessing Monoclonal Antibodies. Biopharm International, 25(9): 22-23, Sept. 2012.
Ultee, ME. New Stroke Drug from ZZ Biotech Produced by Laureate Biopharma, Aug 12, 2012, Press Release.
Ultee, ME. Developing Discoveries into New Therapeutics. Biopharm International, 25(6): 66, June 2012
Valasek, C., Cole, J., Hensel, F., Ye, P., Conner, M.A., and Ultee, M.E. Production and Purification of a PER.C6-Expressed IgM Antibody Therapeutic, Bioprocess
International, Dec. 2011
Reilly J & Ultee ME, Antibody, Purification. In: Encyclopedia of Industrial Biotechnology: Bioprocess, Bioseparation, and Cell Technology, 3rd ed., Flickinger MF, ed. John Wiley & Sons, New York, 2010
Ultee ME & Mullen LJ. Objections Overruled: Single-Use Components in Biopharmaceutical Manufacturing – Opportunities Outweigh Objections, Pharmaceutical Processing, 12-14 (May 2009).
Rea DW, Ultee ME, Chen SX, & Loisel TP. Solutions for Purification of Fc-Fusion Molecules, Biopharm International, March Supplement on Protein Purification, 20-25 (2008).
Ultee ME. Contract Manufacturing goes Mainstream. Focus: J. Reg. Aff. Prof. Soc., 11: 16-20, 2007
Ultee ME & Rea DW: Antibody Purification. In: Encyclopedia of Bioprocess Technology: Fermentation, Biocatalysis and Bioseparation, 2nd ed., Flickinger MF, ed.
John Wiley & Sons, New York, 2001.
Ultee ME, Bridger GJ, Abrams MJ, Longley CB, Burton CA, Larsen SK, Henson GW, Padmanabhan S, Gaul FE, & Schwartz DA: Tumor imaging with
Technetium-99m-labeled hydrazinonicotinamide-Fab' conjugates. J. Nuclear Medicine 38: 133-138, 1997.
Ultee ME: Production & Purification processes for a monoclonal antibody from initial stages through clinical trials. In: Monoclonal Antibody Purification, Minden S & Savage LM, eds., 2.2.1 - 2.2.21. IBC Biomedical Library Series, Southborough, MA, 1996.
Gadam S, Orlando S, Kuriyel R, Pearl S, Mundt S, & Ultee ME: High performance tangential flow filtration (HPTFF) for monoclonal antibody purification: A case study. In: Monoclonal Antibody Purification, Minden S & Savage LM, eds., 1.3.1 - 1.3.4. IBC Biomedical Library Series, Southborough, MA, 1996.
Bridger GJ, Abrams MJ, Padmanabhan S, Gaul F, Larsen S., Henson GW, Schwartz DA, Longley CB, Burton CA, & Ultee ME: A comparison of cleavable and
non-cleavable hydrazinopyridine linkers for the 99mTc labeling of Fab’ monoclonal antibody fragments. Bioconjugate Chemistry 7: 255-264, 1996.
Rea DW & Ultee ME: A novel method for controlling the pepsin digestion of antibodies. J Immunological Methods 157:165-173, 1993.
Rea DW, Mayes T, & Ultee ME: The rapid development of hydrophobic interaction chromatographic purification of a murine monoclonal IgG2a F(ab')2 fragment. J Cell Biochem Supp 17A: 50, 1993.
Rea DW, Ultee ME, Belinka BA, Coughlin DJ, Alvarez VL: Site-specifically radio-iodinated antibody for targeting tumors. Cancer Research (Suppl) 50: 857s-861s, 1990.
Simonson RB, Ultee ME, Hauler JA, Alvarez VL: Radio-immunotherapy of peritoneal human colon cancer xenografts with site-specifically modified 212Bi-labeled
antibody. Cancer Research (Suppl) 50: 985s-988s, 1990.
Simonson RB, Ultee ME, Long CG, Gillette RW, McKearn TJ, Rodwell JD: Inhibition of mannosidase in hybridomas yields monoclonal antibodies with greater capacity for carbohydrate labeling. Clinical Chemistry 34: 1713-1716, 1988.
Ultee ME, Basch RS: N,N'-Bis(4-azidobenzoyl) Cysteine -- A cleavable photo-affinity reagent. Analytical Biochemistry 149: 331-338, 1985.
Matis LA, Hedrich SM, Hannum C, Ultee ME, Lebwohl D, Margoliash E, Solinger AM, Lerner EA, Schwartz RH: The T-lymphocyte response to cytochrome c III. Relationship of the fine specificity of antigen recognition to major histocompatibility complex genotype. J Immunology 128: 2439-2446, 1982.
Hannum C, Ultee M, Matis LA, Schwartz RH, Margoliash E: The major B- and T-cell determinants on pigeon cytochrome c in B10.A mice. In: Atassi MZ, ed.
Immunobiology of Proteins and Peptides II, Adv Exp Med Biol, vol 150, 37-52. Plenum Press, New York, 1982.
Ultee ME, Margoliash E, Lipkowski A, Flouret G, Solinger AM, Lebwohl D, Matis LA, Chen C, Schwartz RH: The T-lymphocyte response to cytochrome c II. Molecular characterization of a pigeon cytochrome c determinant recognized by proliferating T-lymphocytes of the B10.A. Mouse. Molecular Immunology 17: 809-822, 1980.
Solinger AM, Ultee ME, Margoliash E, Schwartz RH: The T-lymphocyte response to cytochrome c I. Demonstration of a T-cell heteroclitic proliferative response
and identification of a topographic antigenic determinant on pigeon cytochrome c, whose immune recognition requires two complementing MHC-linked immune-response genes. J Experimental Medicine 150: 830-848, 1979.
Schwartz RH, Solinger AM, Ultee ME, Margoliash E, Yano JH, Stimpfling JH, Chen C, Merryman CF, Maurer PH, Paul WE: Ir-gene complementation in the murine
T-lymphocyte proliferative response. In: Bach FH, Bonavita B, Vitetta ES, Fox CF, eds. T and B Lymphocytes: Recognition and Function. Academic Press, New York, 1979.
Schwartz RH, Solinger AM, Ultee ME, Margoliash E: Genetic control of the T-lymphocyte proliferative response to cytochrome c. In: Atassi MZ, Stavitsky AB, eds.
Immunobiology of Proteins and Peptides I, Adv Exp Med Biol, vol 98, 371-386. Plenum Press, New York, 1978.
Ultee ME. Top Trends in Bioprocessing for the Next Five Years, BioProcess Online, Oct 24, 2018.
Manzi AE & Ultee ME. Effective CMC Strategy for Biosimilar Development, Chapter in book “Biosimilars: Aspects of Regulatory, Clinical and Biopharmaceutical Development, H. Gutka (ed), Springer AG, 2018.
Ultee, ME & Easton, R. Implications of Cell Culture Conditions on Protein Glycosylation, Biopharm International, 28(11): 20-25, 2015.
Ultee, ME. The Road to the Biologic IND, American Pharmaceutical Review, (18):5 52-58, 2015.
Ultee, ME. Therapeutic Fc-Fusion Proteins, Book Review published in MAbs, 6:4: 810-811, July/August 2014.
Ultee, ME. CMO's Contribution to Bioprocessing, in 11th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production: 61-63, April 2014.
Ultee, ME. Flexibility in Bioprocessing, European Biopharmaceutical Review, Spring 2014, p44-47.
Ultee, ME. New HAE Drug Candidate from Dyax Produced by Laureate Biopharma, Aug 26, 2013, Press Release.
Ultee, ME. Single-Use Technologies Applied Throughout the Development and Manufacturing of Biopharmaceuticals. Bioresearch Online, Guest Column, June
20, 2013.
Ultee, ME. A 25-Year Retrospective on Bioprocessing Monoclonal Antibodies. Biopharm International, 25(9): 22-23, Sept. 2012.
Ultee, ME. New Stroke Drug from ZZ Biotech Produced by Laureate Biopharma, Aug 12, 2012, Press Release.
Ultee, ME. Developing Discoveries into New Therapeutics. Biopharm International, 25(6): 66, June 2012
Valasek, C., Cole, J., Hensel, F., Ye, P., Conner, M.A., and Ultee, M.E. Production and Purification of a PER.C6-Expressed IgM Antibody Therapeutic, Bioprocess
International, Dec. 2011
Reilly J & Ultee ME, Antibody, Purification. In: Encyclopedia of Industrial Biotechnology: Bioprocess, Bioseparation, and Cell Technology, 3rd ed., Flickinger MF, ed. John Wiley & Sons, New York, 2010
Ultee ME & Mullen LJ. Objections Overruled: Single-Use Components in Biopharmaceutical Manufacturing – Opportunities Outweigh Objections, Pharmaceutical Processing, 12-14 (May 2009).
Rea DW, Ultee ME, Chen SX, & Loisel TP. Solutions for Purification of Fc-Fusion Molecules, Biopharm International, March Supplement on Protein Purification, 20-25 (2008).
Ultee ME. Contract Manufacturing goes Mainstream. Focus: J. Reg. Aff. Prof. Soc., 11: 16-20, 2007
Ultee ME & Rea DW: Antibody Purification. In: Encyclopedia of Bioprocess Technology: Fermentation, Biocatalysis and Bioseparation, 2nd ed., Flickinger MF, ed.
John Wiley & Sons, New York, 2001.
Ultee ME, Bridger GJ, Abrams MJ, Longley CB, Burton CA, Larsen SK, Henson GW, Padmanabhan S, Gaul FE, & Schwartz DA: Tumor imaging with
Technetium-99m-labeled hydrazinonicotinamide-Fab' conjugates. J. Nuclear Medicine 38: 133-138, 1997.
Ultee ME: Production & Purification processes for a monoclonal antibody from initial stages through clinical trials. In: Monoclonal Antibody Purification, Minden S & Savage LM, eds., 2.2.1 - 2.2.21. IBC Biomedical Library Series, Southborough, MA, 1996.
Gadam S, Orlando S, Kuriyel R, Pearl S, Mundt S, & Ultee ME: High performance tangential flow filtration (HPTFF) for monoclonal antibody purification: A case study. In: Monoclonal Antibody Purification, Minden S & Savage LM, eds., 1.3.1 - 1.3.4. IBC Biomedical Library Series, Southborough, MA, 1996.
Bridger GJ, Abrams MJ, Padmanabhan S, Gaul F, Larsen S., Henson GW, Schwartz DA, Longley CB, Burton CA, & Ultee ME: A comparison of cleavable and
non-cleavable hydrazinopyridine linkers for the 99mTc labeling of Fab’ monoclonal antibody fragments. Bioconjugate Chemistry 7: 255-264, 1996.
Rea DW & Ultee ME: A novel method for controlling the pepsin digestion of antibodies. J Immunological Methods 157:165-173, 1993.
Rea DW, Mayes T, & Ultee ME: The rapid development of hydrophobic interaction chromatographic purification of a murine monoclonal IgG2a F(ab')2 fragment. J Cell Biochem Supp 17A: 50, 1993.
Rea DW, Ultee ME, Belinka BA, Coughlin DJ, Alvarez VL: Site-specifically radio-iodinated antibody for targeting tumors. Cancer Research (Suppl) 50: 857s-861s, 1990.
Simonson RB, Ultee ME, Hauler JA, Alvarez VL: Radio-immunotherapy of peritoneal human colon cancer xenografts with site-specifically modified 212Bi-labeled
antibody. Cancer Research (Suppl) 50: 985s-988s, 1990.
Simonson RB, Ultee ME, Long CG, Gillette RW, McKearn TJ, Rodwell JD: Inhibition of mannosidase in hybridomas yields monoclonal antibodies with greater capacity for carbohydrate labeling. Clinical Chemistry 34: 1713-1716, 1988.
Ultee ME, Basch RS: N,N'-Bis(4-azidobenzoyl) Cysteine -- A cleavable photo-affinity reagent. Analytical Biochemistry 149: 331-338, 1985.
Matis LA, Hedrich SM, Hannum C, Ultee ME, Lebwohl D, Margoliash E, Solinger AM, Lerner EA, Schwartz RH: The T-lymphocyte response to cytochrome c III. Relationship of the fine specificity of antigen recognition to major histocompatibility complex genotype. J Immunology 128: 2439-2446, 1982.
Hannum C, Ultee M, Matis LA, Schwartz RH, Margoliash E: The major B- and T-cell determinants on pigeon cytochrome c in B10.A mice. In: Atassi MZ, ed.
Immunobiology of Proteins and Peptides II, Adv Exp Med Biol, vol 150, 37-52. Plenum Press, New York, 1982.
Ultee ME, Margoliash E, Lipkowski A, Flouret G, Solinger AM, Lebwohl D, Matis LA, Chen C, Schwartz RH: The T-lymphocyte response to cytochrome c II. Molecular characterization of a pigeon cytochrome c determinant recognized by proliferating T-lymphocytes of the B10.A. Mouse. Molecular Immunology 17: 809-822, 1980.
Solinger AM, Ultee ME, Margoliash E, Schwartz RH: The T-lymphocyte response to cytochrome c I. Demonstration of a T-cell heteroclitic proliferative response
and identification of a topographic antigenic determinant on pigeon cytochrome c, whose immune recognition requires two complementing MHC-linked immune-response genes. J Experimental Medicine 150: 830-848, 1979.
Schwartz RH, Solinger AM, Ultee ME, Margoliash E, Yano JH, Stimpfling JH, Chen C, Merryman CF, Maurer PH, Paul WE: Ir-gene complementation in the murine
T-lymphocyte proliferative response. In: Bach FH, Bonavita B, Vitetta ES, Fox CF, eds. T and B Lymphocytes: Recognition and Function. Academic Press, New York, 1979.
Schwartz RH, Solinger AM, Ultee ME, Margoliash E: Genetic control of the T-lymphocyte proliferative response to cytochrome c. In: Atassi MZ, Stavitsky AB, eds.
Immunobiology of Proteins and Peptides I, Adv Exp Med Biol, vol 98, 371-386. Plenum Press, New York, 1978.